These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 32946836)

  • 1. Safety, immunogenicity, and efficacy of a Clostridioides difficile toxoid vaccine candidate: a phase 3 multicentre, observer-blind, randomised, controlled trial.
    de Bruyn G; Gordon DL; Steiner T; Tambyah P; Cosgrove C; Martens M; Bassily E; Chan ES; Patel D; Chen J; Torre-Cisneros J; Fernando De Magalhães Francesconi C; Gesser R; Jeanfreau R; Launay O; Laot T; Morfin-Otero R; Oviedo-Orta E; Park YS; Piazza FM; Rehm C; Rivas E; Self S; Gurunathan S
    Lancet Infect Dis; 2021 Feb; 21(2):252-262. PubMed ID: 32946836
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of ribaxamase (SYN-004), a β-lactamase, to prevent Clostridium difficile infection in β-lactam-treated patients: a double-blind, phase 2b, randomised placebo-controlled trial.
    Kokai-Kun JF; Roberts T; Coughlin O; Le C; Whalen H; Stevenson R; Wacher VJ; Sliman J
    Lancet Infect Dis; 2019 May; 19(5):487-496. PubMed ID: 30885591
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inactivated varicella zoster vaccine in autologous haemopoietic stem-cell transplant recipients: an international, multicentre, randomised, double-blind, placebo-controlled trial.
    Winston DJ; Mullane KM; Cornely OA; Boeckh MJ; Brown JW; Pergam SA; Trociukas I; Žák P; Craig MD; Papanicolaou GA; Velez JD; Panse J; Hurtado K; Fernsler DA; Stek JE; Pang L; Su SC; Zhao Y; Chan ISF; Kaplan SS; Parrino J; Lee I; Popmihajlov Z; Annunziato PW; Arvin A;
    Lancet; 2018 May; 391(10135):2116-2127. PubMed ID: 29856344
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate in ten countries in Europe and Latin America (HERALD): a randomised, observer-blinded, placebo-controlled, phase 2b/3 trial.
    Kremsner PG; Ahuad Guerrero RA; Arana-Arri E; Aroca Martinez GJ; Bonten M; Chandler R; Corral G; De Block EJL; Ecker L; Gabor JJ; Garcia Lopez CA; Gonzales L; Granados González MA; Gorini N; Grobusch MP; Hrabar AD; Junker H; Kimura A; Lanata CF; Lehmann C; Leroux-Roels I; Mann P; Martinez-Reséndez MF; Ochoa TJ; Poy CA; Reyes Fentanes MJ; Rivera Mejia LM; Ruiz Herrera VV; Sáez-Llorens X; Schönborn-Kellenberger O; Schunk M; Sierra Garcia A; Vergara I; Verstraeten T; Vico M; Oostvogels L;
    Lancet Infect Dis; 2022 Mar; 22(3):329-340. PubMed ID: 34826381
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and immunogenicity of a parenteral trivalent P2-VP8 subunit rotavirus vaccine: a multisite, randomised, double-blind, placebo-controlled trial.
    Groome MJ; Fairlie L; Morrison J; Fix A; Koen A; Masenya M; Jose L; Madhi SA; Page N; McNeal M; Dally L; Cho I; Power M; Flores J; Cryz S
    Lancet Infect Dis; 2020 Jul; 20(7):851-863. PubMed ID: 32251641
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase 1 randomized study assessing safety and immunogenicity of two 3-dose regimens of a Clostridium difficile vaccine in healthy older Japanese adults.
    Inoue M; Yonemura T; de Solom R; Yamaji M; Aizawa M; Knirsch C; Pride MW; Jansen KU; Gruber W; Webber C
    Vaccine; 2019 May; 37(19):2600-2607. PubMed ID: 30962095
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and immunogenicity of different Clostridioides (Clostridium) difficile vaccine formulations in two early phase randomized studies of healthy adults aged 50-85 years.
    Lawrence J; Kitchin N; Anderson AS; Pride MW; Jansen KU; Gruber WC; Peng Y; Yi K; Knirsch C; Webber C
    Vaccine; 2021 Sep; 39(40):5991-6003. PubMed ID: 34483022
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Faecal microbiota transplantation for first or second Clostridioides difficile infection (EarlyFMT): a randomised, double-blind, placebo-controlled trial.
    Baunwall SMD; Andreasen SE; Hansen MM; Kelsen J; Høyer KL; Rågård N; Eriksen LL; Støy S; Rubak T; Damsgaard EMS; Mikkelsen S; Erikstrup C; Dahlerup JF; Hvas CL
    Lancet Gastroenterol Hepatol; 2022 Dec; 7(12):1083-1091. PubMed ID: 36152636
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and Safety of RBX2660 in PUNCH CD3, a Phase III, Randomized, Double-Blind, Placebo-Controlled Trial with a Bayesian Primary Analysis for the Prevention of Recurrent Clostridioides difficile Infection.
    Khanna S; Assi M; Lee C; Yoho D; Louie T; Knapple W; Aguilar H; Garcia-Diaz J; Wang GP; Berry SM; Marion J; Su X; Braun T; Bancke L; Feuerstadt P
    Drugs; 2022 Oct; 82(15):1527-1538. PubMed ID: 36287379
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase 3 study evaluating the lot consistency, immunogenicity, safety, and tolerability of a Clostridioides difficile vaccine in healthy adults 65 to 85 years of age.
    Christensen S; Bouguermouh S; Ilangovan K; Pride MW; Webber C; Lockhart SP; Shah R; Kitchin N; Lamberth E; Zhang H; Gao Q; Brock L; Anderson AS; Gruber WC
    Vaccine; 2023 Dec; 41(50):7548-7559. PubMed ID: 37977942
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety, efficacy, and immunogenicity of a replication-defective human cytomegalovirus vaccine, V160, in cytomegalovirus-seronegative women: a double-blind, randomised, placebo-controlled, phase 2b trial.
    Das R; Blázquez-Gamero D; Bernstein DI; Gantt S; Bautista O; Beck K; Conlon A; Rosenbloom DIS; Wang D; Ritter M; Arnold B; Annunziato P; Russell KL;
    Lancet Infect Dis; 2023 Dec; 23(12):1383-1394. PubMed ID: 37660711
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and immunogenicity of one versus two doses of Takeda's tetravalent dengue vaccine in children in Asia and Latin America: interim results from a phase 2, randomised, placebo-controlled study.
    Sáez-Llorens X; Tricou V; Yu D; Rivera L; Tuboi S; Garbes P; Borkowski A; Wallace D
    Lancet Infect Dis; 2017 Jun; 17(6):615-625. PubMed ID: 28365225
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cadazolid for the treatment of Clostridium difficile infection: results of two double-blind, placebo-controlled, non-inferiority, randomised phase 3 trials.
    Gerding DN; Cornely OA; Grill S; Kracker H; Marrast AC; Nord CE; Talbot GH; Buitrago M; Gheorghe Diaconescu I; Murta de Oliveira C; Preotescu L; Pullman J; Louie TJ; Wilcox MH
    Lancet Infect Dis; 2019 Mar; 19(3):265-274. PubMed ID: 30709665
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of ridinilazole compared with vancomycin for the treatment of Clostridium difficile infection: a phase 2, randomised, double-blind, active-controlled, non-inferiority study.
    Vickers RJ; Tillotson GS; Nathan R; Hazan S; Pullman J; Lucasti C; Deck K; Yacyshyn B; Maliakkal B; Pesant Y; Tejura B; Roblin D; Gerding DN; Wilcox MH;
    Lancet Infect Dis; 2017 Jul; 17(7):735-744. PubMed ID: 28461207
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy, immunogenicity, and safety evaluation of an MF59-adjuvanted quadrivalent influenza virus vaccine compared with non-adjuvanted influenza vaccine in children: a multicentre, randomised controlled, observer-blinded, phase 3 trial.
    Vesikari T; Kirstein J; Devota Go G; Leav B; Ruzycky ME; Isakov L; de Bruijn M; Oberye J; Heijnen E
    Lancet Respir Med; 2018 May; 6(5):345-356. PubMed ID: 29631857
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and efficacy of PfSPZ Vaccine against Plasmodium falciparum via direct venous inoculation in healthy malaria-exposed adults in Mali: a randomised, double-blind phase 1 trial.
    Sissoko MS; Healy SA; Katile A; Omaswa F; Zaidi I; Gabriel EE; Kamate B; Samake Y; Guindo MA; Dolo A; Niangaly A; Niaré K; Zeguime A; Sissoko K; Diallo H; Thera I; Ding K; Fay MP; O'Connell EM; Nutman TB; Wong-Madden S; Murshedkar T; Ruben AJ; Li M; Abebe Y; Manoj A; Gunasekera A; Chakravarty S; Sim BKL; Billingsley PF; James ER; Walther M; Richie TL; Hoffman SL; Doumbo O; Duffy PE
    Lancet Infect Dis; 2017 May; 17(5):498-509. PubMed ID: 28216244
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and efficacy of inactivated varicella zoster virus vaccine in immunocompromised patients with malignancies: a two-arm, randomised, double-blind, phase 3 trial.
    Mullane KM; Morrison VA; Camacho LH; Arvin A; McNeil SA; Durrand J; Campbell B; Su SC; Chan ISF; Parrino J; Kaplan SS; Popmihajlov Z; Annunziato PW;
    Lancet Infect Dis; 2019 Sep; 19(9):1001-1012. PubMed ID: 31399378
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19).
    Barouch DH; Tomaka FL; Wegmann F; Stieh DJ; Alter G; Robb ML; Michael NL; Peter L; Nkolola JP; Borducchi EN; Chandrashekar A; Jetton D; Stephenson KE; Li W; Korber B; Tomaras GD; Montefiori DC; Gray G; Frahm N; McElrath MJ; Baden L; Johnson J; Hutter J; Swann E; Karita E; Kibuuka H; Mpendo J; Garrett N; Mngadi K; Chinyenze K; Priddy F; Lazarus E; Laher F; Nitayapan S; Pitisuttithum P; Bart S; Campbell T; Feldman R; Lucksinger G; Borremans C; Callewaert K; Roten R; Sadoff J; Scheppler L; Weijtens M; Feddes-de Boer K; van Manen D; Vreugdenhil J; Zahn R; Lavreys L; Nijs S; Tolboom J; Hendriks J; Euler Z; Pau MG; Schuitemaker H
    Lancet; 2018 Jul; 392(10143):232-243. PubMed ID: 30047376
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunogenicity and safety of one versus two doses of tetravalent dengue vaccine in healthy children aged 2-17 years in Asia and Latin America: 18-month interim data from a phase 2, randomised, placebo-controlled study.
    Sáez-Llorens X; Tricou V; Yu D; Rivera L; Jimeno J; Villarreal AC; Dato E; Mazara S; Vargas M; Brose M; Rauscher M; Tuboi S; Borkowski A; Wallace D
    Lancet Infect Dis; 2018 Feb; 18(2):162-170. PubMed ID: 29122463
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy, safety, and immunogenicity of the DNA SARS-CoV-2 vaccine (ZyCoV-D): the interim efficacy results of a phase 3, randomised, double-blind, placebo-controlled study in India.
    Khobragade A; Bhate S; Ramaiah V; Deshpande S; Giri K; Phophle H; Supe P; Godara I; Revanna R; Nagarkar R; Sanmukhani J; Dey A; Rajanathan TMC; Kansagra K; Koradia P;
    Lancet; 2022 Apr; 399(10332):1313-1321. PubMed ID: 35367003
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.